Allergy Therapeutics (AGYTF) 0.3600 $AGYTF
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
Research and Markets: Grass Pollen Allergy Therapeutics Pipeline Review, H1 2015 - 9 Companies & 11 Drug Profiles
Business Wire - Tue Jun 09, 8:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqn8d3/grass_pollen) has announced the addition of the "Grass Pollen Allergy - Pipeline Review, H1 2015" report to their offering.
Grass Pollen Allergy Therapeutics Pipeline Review, H1 2015 - 9 Companies & 11 Drug Profiles
M2 - Tue Jun 09, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fx65nx/grass_pollen) has announced the addition of the "Grass Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Grass Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Laboratorios LETI S.L. - Roxall Medizin GmbH Drug Profiles - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Avanz Phleum Pratense - BM-32 - clustoid wiesenlieschgras - gpASIT TM - grass allergy vaccine - Grass-SPIRE - Pollinex Quattro Grass - timothy grass pollen allergen extract For more information visit http://www.researchandmarkets.com/research/fx...ass_pollen
Allergy Therapeutics plc - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:23AM CDT
Research and Markets: Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
Business Wire - Tue Jun 09, 7:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8dm83/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering.
Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g4fb7t/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Stallergenes S.A. Drug Profiles - AllerR - BM-34 - Drug for Ragweed Pollen Allergy - Multi-LAMP-Vax - PL-101 - Pollinex Ragweed - ragweed hypoallergenic vaccin - Ragweed-SPIRE For more information visit http://www.researchandmarkets.com/research/g4...ed_allergy
Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy
Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jjl3r/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Bial - Portela & Ca, S.A. - BioTech Tools s.a. - Circassia Pharmaceuticals plc - Greer Laboratories, Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Laboratorios LETI S.L. - Stallergenes S.A. Drug Profiles - Acaroid - AL-0704rP - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergovac - AllerT - Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Avanz Phleum Pratense - Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Depigoid Birch - Dermatophagoides Pteronyssinus Allergen Extract - gpASIT TM - Grass Pollen Allergoid - Grass-SPIRE - House Dust Mite-SPIRE - JRC2-LAMP-vax - MK-8237 - Olea Europaea Pollen Extract - Pollinex Quattro Grass - Ragweed Pollen Extract - rBet v1 - rBet v1-FV - rPhleum For more information visit http://www.researchandmarkets.com/research/8jjl3r/allergic
Research and Markets: Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
Business Wire - Mon Mar 02, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/d33s2g/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering.
Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Mon Mar 02, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4g5s4/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering. Birch Pollen Allergy - Pipeline Review, H1 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - HAL Allergy BV - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerT - Birch-SPIRE - BM-31 - Drug for Birch Pollen Allergy - PL-102 - rBet v1 - rBet v1-FV For more information visit http://www.researchandmarkets.com/research/d4...rch_pollen
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 43.48 (-0.10), CASM: 1.24 (-0.04), AMRN: 2.41 (+0.02), XON: 46.54 (+1.02), OSIR: 19.31 (+0.65), CPIX: 7.20 (+0.09), AMED: 41.52 (+0.58), CTIC: 1.91 (+0.03), INSY: 37.53 (+0.49), ECYT: 5.43 (+0.17), CMRX: 46.90 (+1.08), KYTH: 74.70 (-0.05), TRIB: 18.05 (+0.17), GALE: 1.63 (+0.10), ARNA: 4.29 (+0.04), XLRN: 30.03 (+0.20), ACRX: 4.20 (+0.02), ENDP: 83.12 (+2.66), DPLO: 48.64 (+1.85), SLXP: 172.96 (+0.15), PPHM: 1.29 (+0.06), MYL: 71.22 (+0.87), CBPO: 111.03 (+7.77), RGEN: 40.28 (+1.65), HALO: 22.78 (+0.38), ALIM: 4.56 (+0.15), ACHN: 8.68 (+0.14), GERN: 4.22 (+0.13), DARA: 0.88 (+0.01), SCMP: 18.15 (+0.87), ICPT: 247.71 (+4.45), CDXS: 3.64 (+0.06), PCRX: 67.54 (+0.20), PBYI: 106.25 (-2.12), FOLD: 14.48 (+0.44)
SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022
M2 - Thu Feb 19, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/jsw5mz/slit_tablets) has announced the addition of the "SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 " report to their offering. Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitize the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms. In the United States, the only licensed route of administration is subcutaneous injection (SCIT). An alternative to SCIT is sublingual immunotherapy (SLIT). The medication is kept beneath the tongue where it is absorbed into the mucosa. Though complex and not fully characterized mechanisms, administration of allergens through the oral, gingival, or sublingual mucosa can decrease the allergic response thus desensitizing the patient by modifying disease at least temporarily if not permanently (i.e. inducing tolerance). The incidence of severe or serious AE associated with SLIT is significantly lower than with SCIT such that SLIT which may be self-administered at home, while safe use of SCIT requires administration in a clinic that is capable of responding to systemic allergic reactions. What You Will Learn - What approved allergy immunotherapeutics (AIT) are currently marketed, how are they administered, what are the device specifics, and who markets them? - Who are the important AIT suppliers, their manufacturing infrastructure and locations, their capabilities? - What are the major factors driving demand for self-administered AIT products including SLIT tablets? - How important are manufacturer relationships and what are the key alliances in the industry? - What are the essential factors, issues, technologies and market development issues for self-administered AIT products? - What are the significant economic, technology, and regulatory factors affecting AIT products? Key Topics Covered: 1. Executive Summary 2. Allergy Immunotherapy Market Dynamics - Competitive Landscape - The Market for Allergy Immunotherapy - Allergen Market Segments - Pollen-based Allergies - Possible Effects of Air Pollution in Allergic Diseases - Dust Mites - Pet Allergies - Food Allergies 3. Therapeutic Market Segments - Named Patient Products - Prescription Products - Emerging Therapeutic Segments - Synthetic Peptide Epitopes - Intralymphatic (ILIT) Administration - Epicutaneous Administration - Next Generation AIT - Recombinant Allergens 4. Allergy Therapeutics Technology Platforms - Contiguous Overlapping Peptides (Anergis) - Sublingual Tablet Immunotherapy - SLIT Tablet Formulations - The Potential Role of Adjuvants 5. Approved SLIT Tablet Products - U.S. - Europe 6. Development-stage Sublingual Allergen Tablets - Birch - Dust Mite - Grass - Ragweed 7. Market Data and Forecasts 8. Market Factors - Regulatory Factors and Issues - United States - Europe - Japan - The Shift from Named Patient to Prescription-based Marketing - The Market Impact on OTC Rhinitis Treatment Products - Clinical Trials and Product Development - Managed Care & Healthcare Economics 9. Company Profiles For more information visit http://www.researchandmarkets.com/research/js...it_tablets
Cedar Pollen Allergy Pipeline Insights Report 2015
M2 - Mon Jan 26, 6:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/btsn6f/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy-Pipeline Insights, 2015" subscription to their offering. This Cedar Pollen Allergy-Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cedar Pollen Allergy. This report provides information on the therapeutic development based on the Cedar Pollen Allergy dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Cedar Pollen Allergy Overview - Cedar Pollen Allergy Pipeline Therapeutics - Cedar Pollen Allergy Therapeutics under Development by Companies - Cedar Pollen Allergy Late Stage Products (Filed and Phase III) - Comparative Analysis - Cedar Pollen Allergy Mid Clinical Stage Products (Phase II) - Comparative Analysis - Cedar Pollen Allergy Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Cedar Pollen Allergy Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Cedar Pollen Allergy - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Cedar Pollen Allergy - Discontinued Products - Cedar Pollen Allergy - Dormant Products - Companies Involved in Therapeutics Development for Cedar Pollen Allergy - Appendix For more information visit http://www.researchandmarkets.com/research/bt...dar_pollen
Ragweed Allergy - Pipeline Insights Report 2015
M2 - Fri Jan 16, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/4552cd/ragweed) has announced the addition of the "Ragweed Allergy-Pipeline Insights" subscription to their offering. This Ragweed Allergy-Pipeline Insights, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Ragweed Allergy. This report provides information on the therapeutic development based on the Ragweed Allergy dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Ragweed Allergy Overview - Ragweed Allergy Pipeline Therapeutics - Ragweed Allergy Therapeutics under Development by Companies - Ragweed Allergy Late Stage Products (Filed and Phase III) - Comparative Analysis - Ragweed Allergy Mid Clinical Stage Products (Phase II) - Comparative Analysis - Ragweed Allergy Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Ragweed Allergy Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Ragweed Allergy - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Ragweed Allergy - Discontinued Products - Ragweed Allergy - Dormant Products - Companies Involved in Therapeutics Development for Ragweed Allergy - Appendix For more information visit http://www.researchandmarkets.com/research/4552cd/ragweed
Global Cedar Pollen Allergy Pipeline Therapeutics Review, H2 2014 - 8 Companies & 11 Drug Profiles
M2 - Wed Jan 07, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrv8ls/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. Drug Profiles - AllerJ - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - Japanese Cedar Hypoallergenic Vaccine - JCC-LAMP-Vax - JRC-LAMP-Vax - MC-LAMP-Vax - Pollinex Quattro Japanese Cedar - RGI-1001 - TO-206 - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/hr...dar_pollen
Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 57.95 (+0.57)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Research and Markets: House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
Business Wire - Fri Sep 26, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z47cwj/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering.
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.
Cedar Pollen Allergy - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qb7s58/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. For more information visit http://www.researchandmarkets.com/research/qb...dar_pollen
Research and Markets: Grass Pollen Allergy Therapeutics Pipeline Review, H1 2015 - 9 Companies & 11 Drug Profiles
Business Wire - Tue Jun 09, 8:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqn8d3/grass_pollen) has announced the addition of the "Grass Pollen Allergy - Pipeline Review, H1 2015" report to their offering.
Grass Pollen Allergy Therapeutics Pipeline Review, H1 2015 - 9 Companies & 11 Drug Profiles
M2 - Tue Jun 09, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fx65nx/grass_pollen) has announced the addition of the "Grass Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Grass Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Grass Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Laboratorios LETI S.L. - Roxall Medizin GmbH Drug Profiles - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Avanz Phleum Pratense - BM-32 - clustoid wiesenlieschgras - gpASIT TM - grass allergy vaccine - Grass-SPIRE - Pollinex Quattro Grass - timothy grass pollen allergen extract For more information visit http://www.researchandmarkets.com/research/fx...ass_pollen
Allergy Therapeutics plc - Product Pipeline Review - 2014
M2 - Tue Jun 09, 7:23AM CDT
Research and Markets: Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
Business Wire - Tue Jun 09, 7:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8dm83/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering.
Ragweed Allergy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 8 Drug Profiles
M2 - Tue Jun 09, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g4fb7t/ragweed_allergy) has announced the addition of the "Ragweed Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ragweed Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ragweed Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Stallergenes S.A. Drug Profiles - AllerR - BM-34 - Drug for Ragweed Pollen Allergy - Multi-LAMP-Vax - PL-101 - Pollinex Ragweed - ragweed hypoallergenic vaccin - Ragweed-SPIRE For more information visit http://www.researchandmarkets.com/research/g4...ed_allergy
Global Pollen Allergy Pipeline Review, H1 2015 - 14 Companies & 31 Drug Profiles
M2 - Fri Jun 05, 5:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3crnf4/pollen_allergy) has announced the addition of the "Pollen Allergy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Biomay AG - BioTech Tools s.a. - Circassia Pharmaceuticals plc - HAL Allergy BV - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - Laboratorios LETI S.L. - REGiMMUNE Corporation - Roxall Medizin GmbH - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - AllerG - Allergen Extract Of Phleum Pratense - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerJ - AllerT - ASP-4070 - Avanz Phleum Pratense - Birch-SPIRE - BM-31 - BM-32 - clustoid wiesenlieschgras - Drug for Birch Pollen Allergy - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - gpASIT TM - grass allergy vaccine - Japanese cedar hypoallergenic vaccine - JCC-LAMP-Vax - MC-LAMP-Vax - Multi-LAMP-Vax - PL-102 - Pollinex Quattro - rBet v1 - rBet v1-FV - RGI-1001 - timothy grass pollen allergen extract - TO-206 - Vaccine for Asthma, Grass Pollen Allergy and Allergic Rhino-Conjunctivitis - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/3c...en_allergy
Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jjl3r/allergic) has announced the addition of the "Allergic Rhino-Conjunctivitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Allergy Therapeutics plc - Anergis SA - Bial - Portela & Ca, S.A. - BioTech Tools s.a. - Circassia Pharmaceuticals plc - Greer Laboratories, Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Laboratorios LETI S.L. - Stallergenes S.A. Drug Profiles - Acaroid - AL-0704rP - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Allergovac - AllerT - Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Avanz Phleum Pratense - Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Depigoid Birch - Dermatophagoides Pteronyssinus Allergen Extract - gpASIT TM - Grass Pollen Allergoid - Grass-SPIRE - House Dust Mite-SPIRE - JRC2-LAMP-vax - MK-8237 - Olea Europaea Pollen Extract - Pollinex Quattro Grass - Ragweed Pollen Extract - rBet v1 - rBet v1-FV - rPhleum For more information visit http://www.researchandmarkets.com/research/8jjl3r/allergic
Research and Markets: Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
Business Wire - Mon Mar 02, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/d33s2g/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering.
Birch Pollen Allergy Therapeutics Pipeline Review H1 2015 - 7 Companies & 9 Drug Profiles
M2 - Mon Mar 02, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/d4g5s4/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2015" report to their offering. Birch Pollen Allergy - Pipeline Review, H1 2015', provides an overview of the Birch Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Allergopharma Joachim Ganzer KG - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - HAL Allergy BV - Stallergenes S.A. Drug Profiles - ALK Birch Pollen Vaccine - Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - AllerT - Birch-SPIRE - BM-31 - Drug for Birch Pollen Allergy - PL-102 - rBet v1 - rBet v1-FV For more information visit http://www.researchandmarkets.com/research/d4...rch_pollen
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 43.48 (-0.10), CASM: 1.24 (-0.04), AMRN: 2.41 (+0.02), XON: 46.54 (+1.02), OSIR: 19.31 (+0.65), CPIX: 7.20 (+0.09), AMED: 41.52 (+0.58), CTIC: 1.91 (+0.03), INSY: 37.53 (+0.49), ECYT: 5.43 (+0.17), CMRX: 46.90 (+1.08), KYTH: 74.70 (-0.05), TRIB: 18.05 (+0.17), GALE: 1.63 (+0.10), ARNA: 4.29 (+0.04), XLRN: 30.03 (+0.20), ACRX: 4.20 (+0.02), ENDP: 83.12 (+2.66), DPLO: 48.64 (+1.85), SLXP: 172.96 (+0.15), PPHM: 1.29 (+0.06), MYL: 71.22 (+0.87), CBPO: 111.03 (+7.77), RGEN: 40.28 (+1.65), HALO: 22.78 (+0.38), ALIM: 4.56 (+0.15), ACHN: 8.68 (+0.14), GERN: 4.22 (+0.13), DARA: 0.88 (+0.01), SCMP: 18.15 (+0.87), ICPT: 247.71 (+4.45), CDXS: 3.64 (+0.06), PCRX: 67.54 (+0.20), PBYI: 106.25 (-2.12), FOLD: 14.48 (+0.44)
SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022
M2 - Thu Feb 19, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/jsw5mz/slit_tablets) has announced the addition of the "SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 " report to their offering. Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitize the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms. In the United States, the only licensed route of administration is subcutaneous injection (SCIT). An alternative to SCIT is sublingual immunotherapy (SLIT). The medication is kept beneath the tongue where it is absorbed into the mucosa. Though complex and not fully characterized mechanisms, administration of allergens through the oral, gingival, or sublingual mucosa can decrease the allergic response thus desensitizing the patient by modifying disease at least temporarily if not permanently (i.e. inducing tolerance). The incidence of severe or serious AE associated with SLIT is significantly lower than with SCIT such that SLIT which may be self-administered at home, while safe use of SCIT requires administration in a clinic that is capable of responding to systemic allergic reactions. What You Will Learn - What approved allergy immunotherapeutics (AIT) are currently marketed, how are they administered, what are the device specifics, and who markets them? - Who are the important AIT suppliers, their manufacturing infrastructure and locations, their capabilities? - What are the major factors driving demand for self-administered AIT products including SLIT tablets? - How important are manufacturer relationships and what are the key alliances in the industry? - What are the essential factors, issues, technologies and market development issues for self-administered AIT products? - What are the significant economic, technology, and regulatory factors affecting AIT products? Key Topics Covered: 1. Executive Summary 2. Allergy Immunotherapy Market Dynamics - Competitive Landscape - The Market for Allergy Immunotherapy - Allergen Market Segments - Pollen-based Allergies - Possible Effects of Air Pollution in Allergic Diseases - Dust Mites - Pet Allergies - Food Allergies 3. Therapeutic Market Segments - Named Patient Products - Prescription Products - Emerging Therapeutic Segments - Synthetic Peptide Epitopes - Intralymphatic (ILIT) Administration - Epicutaneous Administration - Next Generation AIT - Recombinant Allergens 4. Allergy Therapeutics Technology Platforms - Contiguous Overlapping Peptides (Anergis) - Sublingual Tablet Immunotherapy - SLIT Tablet Formulations - The Potential Role of Adjuvants 5. Approved SLIT Tablet Products - U.S. - Europe 6. Development-stage Sublingual Allergen Tablets - Birch - Dust Mite - Grass - Ragweed 7. Market Data and Forecasts 8. Market Factors - Regulatory Factors and Issues - United States - Europe - Japan - The Shift from Named Patient to Prescription-based Marketing - The Market Impact on OTC Rhinitis Treatment Products - Clinical Trials and Product Development - Managed Care & Healthcare Economics 9. Company Profiles For more information visit http://www.researchandmarkets.com/research/js...it_tablets
Cedar Pollen Allergy Pipeline Insights Report 2015
M2 - Mon Jan 26, 6:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/btsn6f/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy-Pipeline Insights, 2015" subscription to their offering. This Cedar Pollen Allergy-Pipeline Insights report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cedar Pollen Allergy. This report provides information on the therapeutic development based on the Cedar Pollen Allergy dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Cedar Pollen Allergy Overview - Cedar Pollen Allergy Pipeline Therapeutics - Cedar Pollen Allergy Therapeutics under Development by Companies - Cedar Pollen Allergy Late Stage Products (Filed and Phase III) - Comparative Analysis - Cedar Pollen Allergy Mid Clinical Stage Products (Phase II) - Comparative Analysis - Cedar Pollen Allergy Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Cedar Pollen Allergy Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Cedar Pollen Allergy - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Cedar Pollen Allergy - Discontinued Products - Cedar Pollen Allergy - Dormant Products - Companies Involved in Therapeutics Development for Cedar Pollen Allergy - Appendix For more information visit http://www.researchandmarkets.com/research/bt...dar_pollen
Ragweed Allergy - Pipeline Insights Report 2015
M2 - Fri Jan 16, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/4552cd/ragweed) has announced the addition of the "Ragweed Allergy-Pipeline Insights" subscription to their offering. This Ragweed Allergy-Pipeline Insights, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Ragweed Allergy. This report provides information on the therapeutic development based on the Ragweed Allergy dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Key Topics Covered: - Ragweed Allergy Overview - Ragweed Allergy Pipeline Therapeutics - Ragweed Allergy Therapeutics under Development by Companies - Ragweed Allergy Late Stage Products (Filed and Phase III) - Comparative Analysis - Ragweed Allergy Mid Clinical Stage Products (Phase II) - Comparative Analysis - Ragweed Allergy Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Ragweed Allergy Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Ragweed Allergy - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Ragweed Allergy - Discontinued Products - Ragweed Allergy - Dormant Products - Companies Involved in Therapeutics Development for Ragweed Allergy - Appendix For more information visit http://www.researchandmarkets.com/research/4552cd/ragweed
Global Cedar Pollen Allergy Pipeline Therapeutics Review, H2 2014 - 8 Companies & 11 Drug Profiles
M2 - Wed Jan 07, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/hrv8ls/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergy Therapeutics plc - Anergis SA - Biomay AG - Circassia Pharmaceuticals plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation - Stallergenes S.A. Drug Profiles - AllerJ - Drug for Japanese Cedar Pollen Allergy - Drugs for Cedar Pollen Allergy - Japanese Cedar Hypoallergenic Vaccine - JCC-LAMP-Vax - JRC-LAMP-Vax - MC-LAMP-Vax - Pollinex Quattro Japanese Cedar - RGI-1001 - TO-206 - Vaccine for Cedar Pollen Allergy For more information visit http://www.researchandmarkets.com/research/hr...dar_pollen
Global Pollen Allergy Clinical Trials Review Report 2014
M2 - Mon Dec 08, 9:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/ml2jdj/pollen_allergy) has announced the addition of the "Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Merck KGaA - Laboratorios LETI S.L. - Merck & Co., Inc. - HAL Allergy BV - Immunomic Therapeutics, Inc. - Circassia Pharmaceuticals plc - Anergis SA Clinical Trial Overview of Top Institutes / Government - Chiba University - University of Yamanashi - Nippon Medical School Hospital - University of Zurich - Medical University of Vienna - Imperial College London - Johann Wolfgang Goethe University Hospitals - Jikei University School of Medicine - The University of Tokushima - University of Fukui For more information visit http://www.researchandmarkets.com/research/ml...en_allergy
MRK: 57.95 (+0.57)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 57.95 (+0.57), NVS: 103.22 (+3.20)
Research and Markets: House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
Business Wire - Fri Sep 26, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z47cwj/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering.
House Dust Mite Allergy Therapeutics Pipeline Review 2014 - 6 Companies & 8 Drug Profiles
M2 - Fri Sep 26, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2h2mn8/house_dust_mite) has announced the addition of the "House Dust Mite Allergy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - DBV Technologies SA - Stallergenes S.A. - Circassia Holdings Ltd. - Anergis SA - Biomay AG Drug Profiles - Actair - allergenic pollen extract of timothy - MK-8237 - House Dust Mite-SPIRE - Subunit Vaccine for Mite Allergy - AllerDM - Viaskin House Dust Mite - PL-103 For more information visit http://www.researchandmarkets.com/research/2h..._dust_mite
Amarantus elects Iain Ross to board
M2 - Mon Sep 01, 3:29AM CDT
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) revealed on Friday the addition of Iain Ross to its board of directors.
